论文部分内容阅读
目的研究紫杉醇联合卡铂治疗卵巢癌的疗效及毒副反应,为卵巢癌的临床治疗提供参考。方法采用随机对照方法将2009年1月至2013年7月手术后经病理检查确诊为Ⅲ~Ⅳ期卵巢癌的96例患者,随机分为治疗组和对照组,每组48例。治疗组48例,采用紫杉醇联合卡铂治疗;对照组48例,采用环磷酰胺联合卡铂治疗。两组患者治疗均以21 d为1个周期。观察并记录两组患者在治疗期间症状的缓解状况、癌灶的大小、病理检查阳性率、药物的不良反应、患者生存质量。6~8个治疗周期后评价疗效,评价指标为化疗反应率和不良反应发生情况。结果 (1)化疗反应率:治疗组完全缓解为14例,部分缓解为26例,总有效率为83.3%;对照组完全缓解为9例,部分缓解为20例,总有效率为60.4%。两组差异有统计学意义(P<0.05)。(2)药物不良反应:两组患者在骨髓移植、消化道反应、肝毒性、肾毒性、心脏毒性、皮肤黏膜毒性、过敏反应、神经毒性及发热等不良反应发生率比较差异无统计学意义(P均>0.05)。结论紫杉醇联合卡铂是治疗卵巢癌的有效方案,临床疗效较好,安全性高,其不良反应可控制,患者可耐受。
Objective To study the efficacy and side effects of paclitaxel combined with carboplatin in the treatment of ovarian cancer and provide reference for the clinical treatment of ovarian cancer. Methods A total of 96 patients with stage Ⅲ-Ⅳ ovarian cancer diagnosed by pathology after operation from January 2009 to July 2013 were randomly divided into treatment group and control group with 48 cases in each group. Forty-eight patients in the treatment group were treated with paclitaxel plus carboplatin, and 48 in the control group were treated with cyclophosphamide combined with carboplatin. Two groups of patients were treated for 21 days for a cycle. Observation and record of the two groups of patients in the treatment of symptoms during the remission, the size of the foci, the positive rate of pathological examination, adverse drug reactions, patient quality of life. After 6 to 8 treatment cycles evaluation of efficacy, evaluation indicators for the response rate of chemotherapy and adverse reactions. Results (1) Chemotherapy response rate: The complete remission rate was 14 in the treatment group, 26 in partial remission, and the total effective rate was 83.3%. The complete remission in control group was 9 and the partial remission was 20. The total effective rate was 60.4%. The difference between the two groups was statistically significant (P <0.05). (2) adverse drug reactions: There was no significant difference in incidence of adverse reactions between the two groups in bone marrow transplantation, gastrointestinal tract reaction, hepatotoxicity, nephrotoxicity, cardiotoxicity, dermal mucosal toxicity, allergic reaction, neurotoxicity and fever P> 0.05). Conclusion paclitaxel combined with carboplatin is an effective treatment of ovarian cancer, clinical efficacy is better, high safety, the adverse reactions can be controlled, patients can tolerate.